Group items tagged

How Reiki training courses for children, teenagers, adults and wise elders help them to relax, instil confidence and act as preventative measure against physical challenges.

If you're looking for a Tricycle, you've come to the right place. We take pride in our expansive selection, which includes REGULAR Tricycle,SINGLE HAND DRIVE Tricycle,DOUBLE HAND DRIVE Tricycle,CHILD MODEL Tricycle and more Still not sure what you're looking for? No Problem. Refer to our TRICYCLE buying guides, where you'll find the information you need to make an informed decision.

The tricycles are individually designed to meet the needs of each disabled child and help provide physiotherapy, build muscle tone and promote play. Italso help benefit growth and development in children with disabilities, enabling them to keep active and retain their independence. Disabled children get huge physical and emotional benefits from having the specially tricycles, which are each custom made to suit the individual child's needs. Riding a tricycle provides both fun and fitness, and is a therapeutic activity that allows children to exercise their lower extremities. As the muscles move through cycling motions, they are flexed, extended and stretched. This range of motion is crucial for children with disabilities, because muscles are incapable of keeping up with bone growth unless fully extended. Tricycles are provided to severely disabled children and adults and come in two sizes, 20 inch and 24 inch models. These trikes are grant funded and to qualify for one of these, an individual must suffer from a condition such as, but not limited to, Cerebral Palsy, Down Syndrome, Traumatic Brain Injury or Autism. Trunk support system is ideal for riders who have trouble remaining upright while seated. An optional headrest is available. A headrest can be purchased with either a flat or contoured headpiece, and adjusts both horizontally and vertically for optimum positioning. The Front Pulley System maintains a level pedal position for children whose extreme tone forces the front of the pedal downward. Turn the oval knob to raise and lower the handlebar. A handbrake for the conventional handlebar will arrive installed on Large tricycle. Open access combined with a low transfer step makes it easy to get on and off trikes. Tricycle Deluxe Double Hand Drive: Frame : Made by E.R.W. Tubes 38.0 mm-16 G. 25.4 mm & 22.22 mm- 18 G. Seat & Back : M S, C.R.C. Sheet. Seat Size 18"x 16" Wheel Size : Wheel Diameter 24"x 1 1/2" Tyre and Tube Standard Company. Pa

Pediatric Manual Wheelchair Pediatric Manual Wheelchair which are fabricated using finest grade raw materials such as Aluminium, MS Steel Pipe, Stainless Steel Pipe. Pediatric Manual Wheelchair is specially designed wheelchairs are suitable for children up to 15 years of age and are capable for 50 kgs. Our range of pediatric wheelchairs are easy to handle and can be used for indoor as well as outdoor purposes.Wheelchairs for kids have smaller frame size to support lighter weight users. Seats are narrow and shallower than compared to adult wheelchairs. They are generally around 14 inches wide and closer to 12 inches deep. Pediatric wheelchairs are specifically designed for children are set a lower to the ground, for the handles to be adjusted according to the adult maneuvering the wheelchair. Features Foldable frame Fixed armrest Foldable footrest Dual brake system Seat-fabric seat with foam Backrest-fabric backrest with foam Total Weight: 17kgs Front wheels: 6" solid wheels, rear wheels-21" solid Self propelling/attendant type Cushion armrest Cerebral Palsy Wheelchair Children Cerebral Palsy (CP) is a group of conditions caused by medical abnormalities in the development of a fetus or the early life of a child.Cerebral palsy can be a difficult condition to live with.Most people who are born with cerebral palsy may suffer from conditions such as partial eye blindness, epilepsy, difficulty with swallowing and even deafness.Cerebral Palsy is a congenital condition which leads to a disorder of movement, balance, muscle control and body posture.CP have to go through rigorous exercise routines to increase and improve their muscle tone, balance and movement. Children with cerebral palsy may experience delayed development of fine motor skills (use of hands), gross motor skills (large movements) and oral motor functioning (eating and speaking).Cerebral palsy affects a person's ability to control their muscles. Muscles can become very stiff or ver

Folding Lightweight Wheelchairs For indoor wheelchair safety the folding power wheelchair models that are lightweight have front casters which turn easily, making them ideal for use in small apartments. Having the casters in front makes this a dangerous chair to use outdoors as the front wheels can turn sharply if encountering a crack in the sidewalk, incline, or rocks.Wheelchair india is manufacturer, supplier, distributor and dealer of Karma KP 10-2 Power Wheelchair for disabled and handicapped in india. They usually have one or two removable batteries and have a similar appearance as the manual wheelchair. They can be controlled with a joystick or a sip and puff method. Lightweight Power Assisted Wheelchairs These chairs can be propelled in a similar manner as the manual wheelchair or use a battery. You may want this type if you want to keep fit and get some exercise but need some power when going up an incline or when traveling a distance. They are smaller and lighter weight than the folding wheelchair and have smaller batteries and motors. Dual Purpose Power Wheelchairs These chairs generally are good for either indoor or outdoor use. You need to have larger wheels in front for outdoors as this is a safety feature. It is better to have six wheels for stability when traveling outdoors. These indoor/outdoor power chairs compromise wheelchair safety and perform poorly when you do not have enough room to turn indoors and you need to travel over rough ground and uneven surfaces. Their optimum performance indoors is when you have wider doors and hallways in assisted living facilities, nursing homes, or homes/apartments. Ideal outdoor surfaces in urban and suburban areas would include sidewalks and paved areas. Outdoor Power Wheelchairs These chairs weigh as much as 400-500 pounds, add the weight of the user up to 250 pounds and the total weight is approximately 650 pounds. They are very efficient outdoors with their rear wheels they can sa

The physicians at Doctors Immediate Care can make sure you've had all the vaccinations you need for children, student, Infant and adults Such as Hep B, HIB, DTaP, IPV, Prevnar, Rotatek, CBC and lead level, MMR, Varicella, Meningococcal , HPV #1, HPV #2, HPV #3, Gardasil

The physicians at Doctors Immediate Care can make sure you've had all the vaccinations you need for children, student, Infant and adults Such as Hep B, HIB, DTaP, IPV, Prevnar, Rotatek, CBC and lead level, MMR, Varicella, Meningococcal , HPV #1, HPV #2, HPV #3, Gardasil

As the government today (November 15) announced plans to expand Britain's booster programme for Covid-19 vaccinations to cover all adults aged over 40, NHS Confederation welcomed the move. The announcement follows the Joint Committee on Vaccination and Immunisation (JCVI) statement that all healthy adults aged 40-49 should be offered a booster, six months after their second dose, and that 16 and 17 year olds should be invited to have a second dose. Accepting the JCVI's advice, health and social care secretary Sajid Javid said: "All 4 parts of the UK intend to follow the JCVI's advice. "We know immunity to Covid-19 begins to wane after 6 months and new data published today shows a third dose boosts protection against symptomatic infection to more than 90% - this highlights just how important it is that everyone eligible gets their top-up jabs as soon as possible."

Researchers have projected the rates of liver disease and associated deaths due to increased alcohol consumption during the Covid-19 pandemic. The research has been published in the 'Hepatology Journal'. A team led by investigators at Massachusetts General Hospital used data from a national survey of US adults on their drinking habits that found that excessive drinking (such as binge drinking) increased by 21 per cent during the Covid-19 pandemic. The scientists simulated the drinking trajectories and liver disease trends in all US adults. They estimated that a one-year increase in alcohol consumption during the Covid-19 pandemic will result in 8,000 additional deaths from alcohol-related liver disease, 18,700 cases of liver failure, and 1,000 cases of liver cancer by 2040. In the short term, alcohol consumption changes due to Covid-19 are expected to cause 100 additional deaths and 2,800 additional cases of liver failure by 2023. The researchers noted that a sustained increase in alcohol consumption for more than one year could result in 19-35 per cent additional mortality.

As part of efforts to streamline spending and enhance resource allocation within the healthcare system, the NHS has chosen to cease providing the free vaccinations for all, which were initially introduced in 2020. Approximately 12 million British citizens will not have access to free flu vaccinations and Covid-19 boosters during the upcoming winter, according to NHS. Furthermore, the NHS plans to defer flu vaccine distribution to October, aiming to heighten protection for those aged 65 and older and other eligible groups in the high-risk winter months. However, this has stirred panic among pharmacies, given their advanced planning based on the initial start date of September 1 for vaccinations. On Tuesday (Aug. 8), the Joint Committee on Vaccination and Immunisation (JCVI) released NHS guidelines indicating that Covid-19 booster shots, starting from autumn, will not be provided to individuals aged 50 to 64 who are in otherwise good health. Similar guidance had already been released for flu, rendering 12 million middle-aged Britons ineligible for free jabs, JCVI said. Prior to the pandemic, influenza vaccinations were available to healthy adults aged over 65, alongside children and younger adults with medical conditions. Amidst the pandemic, the distribution of flu vaccinations was expanded to include individuals aged 50 to 64, in alignment with the criteria for Covid-19 boosters.

The recent data released by the NHS England revealed that in 2022/23 nearly 86 million antidepressant items were prescribed to around 8.6 million identified patients. According to the statistic published on 'Medicines Used in Mental Health' of the 5 British National Formulary (BNF) sections, 4 had increases in items and identified patients across 2022/23. The only BNF section to decrease since 2021/22 was hypnotics and anxiolytics. Items fell by 2% to 14 million and identified patients fell by 2 per cent to 1.9 million in 2022/23 The data also revealed that Prescribing of Central Nervous System (CNS) stimulants and drugs for ADHD increased by 32 per cent in adults over 18 and 12 per cent in children 17 and under. "2022/23 was the first time that more adult patients have been prescribed drugs from this section than child patients, in the time period covered by these statistics," said the report.

Adults who are overweight or obese and have type 2 diabetes or prediabetes are at a higher risk of developing severe health issues, according to authors of a recent study. Experts. however, disagree on the best dietary regimens and supportive measures to suggest. The latest study was published in the journal 'The Annals of Family Medicine'. In the findings, researchers used a 2×2 diet-by-support factorial design to randomise 94 adults with the aforementioned conditions, contrasting a very low-carbohydrate (VLC) or ketogenic diet with a Dietary Approaches to Stop Hypertension (DASH) diet. They also determined the outcomes of interventions that included and excluded additional support practices like mindful eating, effective emotion regulation, social support, and cooking instruction. Using intent-to-treat analyses, the VLC diet led to greater improvement in estimated mean systolic blood pressure (SBP; -9.8 mmHg vs. -5.2 mmHg, P =.046), greater improvement in glycosylated haemoglobin (HbA1c; -.4 per cent vs. -.1 per cent, P = 0.034), and greater improvement in weight (-19.14 lbs vs. -10.33 lbs, P = 0.0003), compared to the DASH diet. The addition of extra support did not have a statistically significant effect on outcomes.

Over the past two years, the Covid pandemic has resulted in a backlog of elective care within the NHS, with record numbers of patients on waiting lists across the UK. Despite efforts to catch up after the first wave, subsequent waves have put further strain on an already stretched NHS system. This has had a tremendous impact on many patients waiting for routine dermatology appointments and, while every effort has been made to see patients with suspected serious skin cancers within two weeks, this target is not always achieved. With rising waiting times, pharmacists are increasingly the first port of call for patients suffering with a broad range of skin problems. From acne and rosacea, eczema or psoriasis, to changing skin lesions or simple insect bites, pharmacists can give helpful advice, allowing some customers to find quick relief to their skin complaint in mild cases, while directing others to see their GP without delay. Below is some practical advice that pharmacists can give to their customers with commonly encountered skin complaints. Acne Acne is a common skin condition that not only affects teenagers but adults too. It is estimated that up to 40 per cent of women continue to suffer with acne into their adult years. Acne has been linked to an increased incidence of depression, anxiety and even suicidal ideation. Patients have reported feeling overlooked and often dismissed in their concerns by health care professionals. Unfortunately, these issues have been further compounded by delays in being seen and treated due to the ongoing Covid pandemic. Pharmacists are well placed to help acne patients choose the right skincare. This should consist of lightweight products, such as gel or milky cleansers, with moisturisers in serum, lotion or light cream preparations. Some acne suitable products are further labelled as non-comedogenic. Oil-based or occlusive preparations are best avoided. There are many good quality, non-comedogenic sun blocks suited

The Scottish Medicines Consortium (SMC) has accepted AbbVie's RINVOQ (upadacitinib) for use within NHS Scotland for the treatment of adult patients with moderately to severely active ulcerative colitis (UC). Upadacitinib offers an additional treatment choice in the therapeutic class of janus kinase inhibitors. "Daily life with ulcerative colitis is difficult due to the debilitating and unpredictable nature of its symptoms", said Dr Jonathan Macdonald, Consultant Gastroenterologist at NHS Greater Glasgow and Clyde. "Clinical trials have shown that upadacitinib as a once daily pill controls symptoms in eight weeks for many patients and provided sustained responses at one year. The SMC's decision is good news for people with ulcerative colitis in Scotland as it provides an additional treatment option to help them gain control of their condition." The SMC decision is based on data from the induction studies U-ACHIEVE and U-ACCOMPLISH, as well as the Phase 3 U-ACHIEVE maintenance study, which demonstrated the efficacy of upadacitinib versus placebo in its ability to achieve clinical remission. The SMC's decision follows the granting of Marketing Authorisation for upadacitinib in UC in July 2022.

National Institute of Health and Care Excellence (NICE) has not recommended 'Tirzepatide', also known as Mounjaro, developed by Eli Lilly, in its draft guidance issued on Tuesday (27 June) for treating type 2 diabetes in adults alongside diet and exercise. The independent NICE committee recognised the importance of new treatment options given that fewer than two-thirds of the adults with type 2 diabetes have adequate glucose control when using current treatment options. Evidence submitted to the committee from clinical trials showed the use of tirzepatide at any dose resulted in better glucose control and lower weight compared with semaglutide or insulin therapy. The weight reduction was more pronounced with higher doses of tirzepatide, while the effect on glucose levels seemed less dose-dependent. Similar effects were observed against all GLP-1 receptor agonists in company's network meta-analysis, but this was uncertain. The committee have asked the company to provide more data to address the uncertainties in the clinical evidence, when compared to all relevant alternative treatments.

The National Pharmacy Association (NPA), released survey data today (30 October) which suggests Britons have a higher regard for community pharmacies than retail settings. It also highlighted the level of awareness of pharmacies' healthcare duties, which range from NHS medicines consultations to monitoring blood pressure. The survey conducted by Research Without Barriers involved 1680 adults in England from 20-23 October 2023. The data showed that over 90 per cent of adults in England are aware that pharmacies offer each of these services. The survey also suggested that 56 per cent of respondents find it appropriate to ask their local pharmacies for help to quit smoking, and 63 per cent would ask for a blood pressure check.

The National Institute for Health and Care Excellence (NICE) has recommended faricimab as treatment option for adults with wet age-related macular degeneration or diabetic macular oedema. Thousands of people in England could benefit from the recommendation of a new drug that helps to treat two leading causes of sight loss and visual impairment. Faricimab is administered as an eye injection and is being recommended as an option for treating some adults with wet age-related macular degeneration (AMD) or with diabetic macular oedema (DMO). In the key clinical trials, aflibercept, another eye injection drug used to treat AMD and DMO, was administered every 8 weeks, while faricimab dosing, based on assessments of the disease activity, allowed for an interval of up to 16 weeks between doses, and was found to be equally effective. Up to 300,000 people in England with wet age-related macular degeneration (AMD) could be eligible to receive faricimab as part of their treatment alongside just over 28,000 people with diabetic macular oedema.

Recently launched generic version of Apixaban by Teva UK is said to bring savings to the NHS drug bill while making sure patients get the medicine they need. The generic apixaban is available for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA) and treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. Previously there was only a 'branded' product available, but Castleford-based Teva UK succeeded in invalidating the apixaban patent and SPC (supplementary protection certificate) in the UK High Court and so is now able to launch its own 'generic' version - which will bring savings for the NHS while making sure patients get the medicine they need. "We've always said that we stand up for the patient", said Kim Innes, General Manager of Teva UK and Ireland. "The launch of generic apixaban emphasises Teva's commitment to doing the right thing by putting patients at the heart of everything we do by giving them and the NHS access to affordable treatments." Apixaban is an anticoagulant which directly inhibits factor X (factor Xa), inhibiting thrombin formation and the development of thrombi (blood clots). For at-risk patients, such as those with, or at risk for DVT, or NVAF, the risk of stroke related to blood clots forming in the body and traveling to the brain is a serious concern. Each year, DVT affects around 1 person in every 1,000 in the UK and if left untreated, about 1 in 10 people with a DVT will develop a PE.

The National Institute for Health and Care Excellence (NICE) has issued draft guidance on 'Evusheld' which is not recommended for vulnerable adult with high risk of severe Covid-19 on Thursday (16 February). The draft guidance is open for public consultation until 9 March 2023. The committee will consider any comments received at a meeting currently due to take place on 4 April 2023. It comes after last month's decision by the US drug regulator to withdraw its emergency use authorisation for Evusheld as a preventative treatment for Covid-19, which said there was insufficient evidence that Evusheld is effective against the dominant variants of Covid-19 in the US. NICE's independent appraisal committee has reached the same conclusion having considered evidence which shows Evusheld is unlikely to prevent infection with most of the variants circulating in the UK now and in the near future. It has also announced that it is developing a new review process to update recommendations on the cost-effectiveness of Covid-19 treatments so they can be made available more quickly to patients if they show promise against new variants and are found to be cost-effective.

The latest formulation of XGEVA (denosumab) is now available to patients in the UK, offering a more convenient treatment option for bone metastasis. It is the first product to be authorised by the Medicines and Healthcare products Regulatory Agency (MHRA) via the new International Recognition Procedure (IRP). Denosumab (XGEVA) is used to prevent serious bone-related complications resulting from bone metastasis in adults and to treat giant cell tumour of bone in both adults and adolescents. The medicine was authorised on 29 February 2024 as a 120 mg solution for injection in a prefilled syringe. In contrast to the current vial presentation, this simplifies the administration process, reducing the volume of liquid injected and lowering the risk of dosing errors. The product was authorised in 30 days by the MHRA, thanks to the new IRP that facilitated a rapid approval process.

The World Health Organization (WHO) reiterated its concerns about tobacco companies' continued targeting of young people through various channels such as social media, sports, and music festivals, as well as the introduction of flavored products. In a joint report with industry watchdog STOP released on Thursday, the WHO accused these companies of attempting to ensnare a new generation in nicotine addiction. While facing stricter regulations on traditional cigarettes, major tobacco firms and newcomers have turned to alternatives like vapes, arguing they are intended for adult smokers. However, the WHO and STOP highlighted in their report that these products often appeal to youth, with their attractive designs and fruity flavors making them more appealing to children than to adults in many countries.